Jenkoo

@tom_the_bomb__ @PJ_Crabb @JStonker I see your valid point Tom. Perhaps awaiting for BTD for 6k simultaneously allows Avacta to understand if 6103 in human results in early efficacy is the right approach. Once 6103 shows early signs then that would de-risk Gen2 allowing for Gen1 partners 🤔 Interesting 👍🏻

@Jenkoool @PJ_Crabb @JStonker Now we've got to dosing without a deal, I'd rather they retained SGC incase Gen2 doesn't perform (confident it will). SGC is a near term rev generator, so I'd like that retained. They have so many options when it comes to non-dilutive funding - don't ditch your lead asset IMO.

"There's an incredible amount of interest in AVA6103... the company's strategy at this point is to protect this asset until we have sight of the initial human data, such is its value." #AVCT July 2025. FIH any minute now ⏳

@PJ_Crabb @tom_the_bomb__ @JStonker Personally think we should make a deal on 6k SGC to fund P1 of 6103. Only reason to delay 6k deal imo is extended cont’ of PFS or if #avct expect to receive Breakthrough Designation which either would 📈 £deal price. I trust CC either-way. Her performance has earned that much 👍🏻

@tom_the_bomb__ @Jenkoool @JStonker Why when they can sign a Gen 1 (6000) deal now and get as much as pos for 6103. That won’t be seen through beyond this year if data as good as expected. We just need cash for audit so 6000 deals on SGC, STS ASAP.

@tom_the_bomb__ @JStonker ❤️ I can’t see a scenario where Avacta are not taken out during 6103 P1. Suspect it’s late this year or early next, but if 6103 performs; BP will not sit on their hands, nor let #avct keep the tech through fear of significant competitor trajectory. ‘Multiple shots on goal’

@JStonker Translation: “We intend to wait… unless someone pays us enough not to.” And given (1) the recent Enhertu comparison, (2) platform validation via AVA6000 & (3) growing third party validation …it’s highly likely that timeline flexibility exists behind the scenes. #AVCT ⏰

@tom_the_bomb__ I wonder, if 6103 delivers anything like it’s potential, will we see some aggressive buys from the people in the data room and potentially investors connected to patients. Avacta have become much better at controlling leaks, but far from perfect.

I can see the #AVCT share price starting to gain some momentum over the next few months. Too much news flow that could land at any moment. #Biotech

CC’s quote - Emphasises that success is a direct result of hard work, effort, & dedication rather than chance. It highlights that there are no shortcuts to achieving goals & that labor must precede accomplishment. #avct

@neutronicLSE @MylesMcNulty @avacta We are in the ‘deal window’ which has been mentioned by BoD & shared on presentation timelines. They’ve also said they are not taking 6k into P2 without a partner. unless they are sitting on hands, I it’s certain they are discussing. The removal of Max Dosing enhances deal values

@Jenkoool @MylesMcNulty @avacta How do we know the first is happening now?

A historic period for @avacta approaches. In the next 2 weeks or so, the first patients will be dosed in the Phase 1 trial for AVA6103 - 'the Beast', as it's referred to inside the halls of #AVCT. The company last month detailed how AVA6103 enjoys a number of key advantages over the world's best-selling antibody-drug conjugate, Enhertu. The pre-clinical models for 6103 in the public domain reveal a complete response rate of >90%. The Phase 1 trial is initially focusing on four indications: pancreatic, cervical, gastric and small cell lung cancer. If all is going well in the first few months, it would not surprise to see the trial expanded to include colorectal (given how impressive the pre-clinical results were in this indication), and possibly others. Analysts have Enhertu achieving peak sales of $10bn to $12bn in a few years' time. What has inexplicably not been covered by equity analysts yet is that 6103 could have a total addressable market of 5 times, possibly 10 times, that of Enhertu. And, due to its significantly superior targeting, it should simultaneously demonstrate significantly higher efficacy and reduced side effects, relative to Enhertu. In the meantime, Avacta's (current) lead asset, AVA6000, has continued to generate superb data in its Phase 1b trial, notably for salivary gland cancer - for which it is likely to at least double the historic benchmark PFS. SGC is a $250m per annum opportunity. A registrational Phase 2 trial for 6000 targeting this indication should kick off this summer (subject to funding). Management would never state this publicly, but I suspect they consider the probability of AVA6000 receiving marketing approval for SGC to be ~90% now. Does the company now joint venture it, so that a larger partner can help fund it through Phase 2 before sales can commence? Or license it out, for a free carry and then royalties (possibly with a small upfront cash sum)? Or could AVA6000 (for SGC only) just be sold in full, for a large cash sum? The last option would probably be the worst-value (for existing shareholders) in the long-term, as a result of missing out on a share of 5+ years of >$200m per annum, high-margin sales. On the other hand, it would minimize equity dilution for the foreseeable, and ensure that Avacta can keep 6103, 100%-owned through to at least the start of Phase 2. Moreover, one could argue that if 6103 performs in clinic as management thinks / hopes(!) it will, then it's highly likely that the company would be acquired before it can enjoy any royalties / profit share from 6000 SGC sales. In any event, I am certain that the company now has an array of attractive options before it, to fund operations and growth. To think that this year - in the next 6-9 months - we will know if pre|CISION is likely going to disrupt the global oncology market, and ultimately displace the budding ADC class (not to mention, the very large majority of conventional chemotherapy). This company could become a national treasure. All the information and data is in the open for everyone to peruse, and realize this. As I have highlighted previously, the international peer group for precision oncology has demonstrated that 100x returns from Avacta's current mkt cap of £300m are entirely possible, within a relatively short timeframe (2-3 years). I am looking forward to truly frenzied buying here in the not-too-distant.

@DomPosen @MylesMcNulty @avacta Agree. They are too concerned with votes to care for the very country and people they were elected to represent 😔

@MylesMcNulty @avacta It’s shocking that UK gov has no system in place to financially support company like #AVCT with grants to ensure they can thrive and remain in depended if possible and paying as much taxes in our country as possible. Wasted opportunity.

@Biotech2k1 Thanks. Certainly recommend you take a couple of hours to scratch the surface if you get chance. The platform PDC’s are showing great promise for 90+% of solid tumours & has wonderful adaptability due to its linkers and capping groups Recently the Dox max dosing limit was removed

@Jenkoool Interesting high risk spec. I say treat it like a lottery ticket. Don't risk more than you are willing to lose.

I am doing an open post. I usually only make it so that people I follow can reply. That is to keep out all the bots. If you like to talk biotech, and want me to follow you please reply and I will gladly follow you.

@AndrewDigby3 @Biotech2k1 That’s ok. I asked for option and received one.

@Jenkoool @Biotech2k1 Based on that answer J, I bet you wished you hadn’t asked? #AVCT

@neutronicLSE I wonder how many of the 500 precision medicines created have been at the request of others…?!?

@Jenkoool I was researching Topotecan the other night trying to find the Novartis link.

DNA damage markers appear as early as 1h after dosing current Topo1 inhibitors. Peak accumulation 16-24hours Apoptosis (clearing damaged DNA) 24-72h after dosing depending on dose Significant apoptosis builds over 1–3 days (DNA damage accumulates @ cell division) #avct

@jivetur88775834 This post was instigated by the Q4 data release marker on the timeline. The research above suggest avacta will know quickly how 6103 is performing. By mid April they will have learnt a lot about the drug and its early potential

@jivetur88775834 Indicators like γ-H2AX foci (a marker of DNA double-strand breaks) can appear early as 1 hour after exposure. Would be interesting to know if #avct plan to look for this marker. I’m not suggesting complete response <week just that tumour shrinkage is possible given pkk 👍🏻

#avct are re-writing the rules. IMO clinicians will know if 6103 is having an effect on Tumours within the first week. #avct may need to adopt increase screening to capture the speed at which 6103 works. Post 1-4 summarising Grok Post 5 - IMO

For AVA6103-like conjugates, preclinical data for exatecan delivery show high tumor concentrations sustained over 5 days with plasma clearance in ~2 hours, suggesting efficacy could begin manifesting (e.g. via tumor shrinkage in models) within days after the initial dose. #avct

My favourite slide in the deck…. AND my 2 favourite snippets from the ‘must hear’ presentation #avct Superb